Boehringer Ingelheim reports positive long-term efficacy data for Ofev

Boehringer Ingelheim has announced data from a clinical trial showing the sustained long-term efficacy of its idiopathic pulmonary fibrosis drug Ofev.

Data from the INPULSIS-ON extension trial has confirmed the efficacy and safety of Ofev, showing its long-term effect on slowing disease progression and its manageable side effect profile.

The beneficial effect of Ofev was maintained and the change from baseline in forced vital capacity demonstrated to be consistent over two years.

It was also demonstrated that commonly-used concomitant medications, such as anti-acids or systemic steroids, did not influence the beneficial effect of Ofev on slowing disease progression.

Professor Luca Richeldi, professor of respiratory medicine at the University of Southampton, said: "The safety and efficacy data presented for Ofev is very reassuring with regards to the long-term outcomes of treatment with Ofev and its effect on slowing disease progression."

This comes after the drug was included in updated international treatment guidelines for idiopathic pulmonary fibrosis from the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association earlier this year.